Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission After 2 Cycles of Chemotherapy ?
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 183
- 试验地点
- 1
- 主要终点
- Compare the survival without progress of transplanted patients versus not transplanted patients
研究概览
简要总结
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion.
This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with High Risk Big B Cells Lymphoma
- •Age > 18 years
排除标准
- •Not applicable
结局指标
主要结局
Compare the survival without progress of transplanted patients versus not transplanted patients
时间窗: From the date of complete remission post C2 of chemotherapy up to 120 months
Medical follow up
次要结局
- Cumulative Relapse Incidence(From the date of complete remission post C2 of chemotherapy up to 120 months)
- Overall survival(From the date of complete remission post C2 of chemotherapy up to 120 months)